SRPT : Summary for Sarepta Therapeutics, Inc. - Yahoo Finance

U.S. Markets open in 1 hr 53 mins

Sarepta Therapeutics, Inc. (SRPT)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
28.68+0.40 (+1.41%)
At close: 4:00PM EST
People also watch
ACADCLVSPTCTCLDXICPT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close28.28
Open28.88
Bid28.54 x 1000
Ask28.99 x 300
Day's Range28.08 - 29.00
52 Week Range8.00 - 63.73
Volume2,139,772
Avg. Volume2,403,827
Market Cap1.57B
Beta2.21
PE Ratio (TTM)-5.45
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals18 hours ago

    Did Gilead's new tool for speeding drug approval come at bargain-basement price?

    Gilead Sciences Inc. spent $125 million for a voucher that could speed FDA review of a drug, but one analyst said the seller may have undervalued the asset. Sarepta Therapeutics of Cambridge, Mass., on Tuesday said it sold the so-called priority review voucher to Foster City-based Gilead Sciences Inc. (GILD). Sarepta (SRPT) had received the rare pediatric disease voucher when the Food and Drug Administration approved its Duchenne muscular dystrophy drug, Exondys51, in September.

  • Investopedia21 hours ago

    Sarepta Sells Priority Review Voucher for $125M

    Sarepta sold its Priority Review Voucher for $125 million to Gilead.

  • TheStreet.com21 hours ago

    Sarepta Leads Biotech Movers on Voucher Deal News

    Gilead (finally!) has acquired something from Sarepta, even if it is quite small.